LCM
IBB icon

LionEye Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

LionEye Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-270,000
Closed -$27.3M – 7
2015
Q3 		$27.3M Buy
+270,000
New +$32.4M 1.13% 17

Other funds holding IBB

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

LionEye Capital Management's IBB Position: Q4 2015 in Review

LionEye Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2015, closing a stake of 270,000 shares — an estimated $27.3M sold.

LionEye Capital Management first reported a position in IBB in Q3 2015 and held it in 1 quarter. The position peaked at $27.3M in Q3 2015. 431 funds tracked by Wall St. Rank hold IBB as of Q4 2015.

  • LionEye Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2015 after selling out during the quarter.
  • LionEye Capital Management sold 270,000 iShares Biotechnology ETF shares in Q4 2015, an estimated $27.3M.
  • LionEye Capital Management first reported a position in iShares Biotechnology ETF in Q3 2015 and held it in 1 quarter.
  • LionEye Capital Management's iShares Biotechnology ETF position peaked at $27.3M in Q3 2015.
  • 431 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2015.

Based on LionEye Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.